Skip to main content
Neurology

FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment

In clinical trials, patients with Parkinson disease who were treated with foscarbidopa/foslevodopa experienced superior improvement in ON time without dyskinesia compared with oral immediate-release carbidopa/levodopa.:

Source: Neurology Read More

Related Posts

Neurology <![CDATA[10 Years of Progress: A Timeline of FDA Approvals for Duchenne Muscular Dystrophy]]>

<![CDATA[10 Years of Progress: A Timeline of FDA Approvals for Duchenne Muscular Dystrophy]]>

September 18, 2026
Neurology <![CDATA[Study Reveals Higher EBNA1 Antibodies Associated With Reduced Disability Progression in MS ]]>

<![CDATA[Study Reveals Higher EBNA1 Antibodies Associated With Reduced Disability Progression in MS ]]>

September 18, 2026
Neurology <![CDATA[FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis]]>

<![CDATA[FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis]]>

September 17, 2026